Spyre Therapeutics Announces Grants of Inducement Awards

The awards were material to two employees’ acceptance of employment and carry service-based vesting requirements.

Rhea-AI Summary

Spyre Therapeutics (SYRE) announced equity inducement awards for two non-executive employees, approved by its independent Compensation Committee on November 2, 2026.

The awards comprise options to purchase 11,138 shares and 3,195 restricted stock units under the 2018 Equity Inducement Plan. The options have a 10-year term and a $95.51 exercise price, equal to the November 2 closing share price. Options vest one-fourth on the first anniversary of each employee’s start date, then one-forty-eighth monthly. Restricted stock units vest one-fourth on each anniversary of the next November 15 occurring on or after the employee’s start date. All vesting requires continuous service.

Positive

• Minor pointEquity inducement awards were material to two non-executive employees’ acceptance of employment.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Options covering 11,138 shares at $95.51 and 3,195 restricted stock units create potential shareholder dilution.

Key Figures

Stock options: 11,138 shares Restricted stock units: 3,195 RSUs Exercise price: $95.51 per share +1 more

Stock options

11,138 shares

Inducement awards to two non-executive employees

Restricted stock units

3,195 RSUs

Inducement awards to two non-executive employees

Exercise price

$95.51 per share

Stock options; equal to the November 2 closing price

Option term

10 years

Stock options

Historical Context

1 past event · Latest: Oct 02

1 event

1. Oct 02

   Inducement awards

   24h Move

   -0.5%

   Prior inducement awards included 21,424 options, 6,604 RSUs, and a 10-year option term.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4)

2 terms

restricted stock units financial

"3,195 restricted stock units (“RSUs”) to two non-executive employees"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 11,138 shares of common stock of Spyre and 3,195 restricted stock units (“RSUs”) to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on November 2, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted with a 10-year term and an exercise price equal to $95.51, the closing price per share of Spyre's common stock as reported by Nasdaq on November 2, 2026. The options granted to the employees shall vest and become exercisable as to one-fourth (1/4^th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48^th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The RSUs granted to the employees shall vest as to one-fourth (1/4^th) of the shares subject to the respective RSUs on each anniversary of the next November 15 occurring on or after the employee’s start date, subject to continuous service with Spyre through the applicable vesting dates. The stock options and RSUs are subject to the terms of the 2018 Plan.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.

For more information, please visit http://spyre.com.

For Investors:
Eric McIntyre
SVP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity inducement awards did Spyre Therapeutics approve?

Spyre approved options to purchase 11,138 shares and 3,195 restricted stock units for two non-executive employees on November 2, 2026. The options have a $95.51 exercise price and a 10-year term.

How do Spyre Therapeutics’ employee inducement awards vest?

The options vest one-fourth on the first anniversary of each employee’s start date and one-forty-eighth monthly thereafter. Restricted stock units vest one-fourth on each anniversary of the next November 15 occurring on or after the employee’s start date. Both awards require continuous service through the applicable vesting dates.